SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, superior bystander killing effect and favorable safety profiles

Ting Zhang(National Institutes of Health), Feng He(Jiangsu Hengrui Medicine (China))

Research Square

December 29, 2023

10.21203/rs.3.rs-3770094/v1

Cited by 2

Related Papers

Protection of photoreceptors by intravitreal injection of the Y-27632 Rho-associated protein kinase inhibitor in Royal College of Surgeons rats

|Molecular Medicine Reports|2015|24

Proteomic characterization of endogenous substrates of mammalian ubiquitin ligase Hrd1

|Cell & Bioscience|2018|24

Dihydroartemisinin inhibits the viability of cervical cancer cells by upregulating caveolin 1 and mitochondrial carrier homolog 2: Involvement of p53 activation and NAD(P)H:quinone oxidoreductase 1 downregulation

|International Journal of Molecular Medicine|2017|23

Uncoupling Protein 2 Deficiency Enhances NLRP3 Inflammasome Activation Following Hyperglycemia-Induced Exacerbation of Cerebral Ischemia and Reperfusion Damage In Vitro and In Vivo

|Neurochemical Research|2021|14

1,25‑dihydroxyvitamin D3 enhances the susceptibility of anaplastic thyroid cancer cells to adriamycin‑induced apoptosis by increasing the generation of reactive oxygen species

|Molecular Medicine Reports|2019|8